In the plan, CMS proposed to exclude cell and gene therapies from comprehensive ambulatory payment classifications while the agency collects more data on how those therapies function for one year.
While ASCO said it supports that aspect of the proposal, it expressed concern that Medicare beneficiaries would, “continue to face barriers accessing CAR T-cell therapy unless providers are reimbursed equitably for this treatment,” according to a Sept. 10 news release from the association.
ASCO said the one-year time frame for data collection is “insufficient” and recommended CMS extend the time frame to amass “transparent meaningful data,” the news release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
